A tribute to Eberhard F. Mammen, M.D. (1930-2008)

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 8, 2008, Pages 703-707

  Favaloro, Emmanuel J ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING; CARDIOVASCULAR RISK; DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; HEMOSTASIS; PREECLAMPSIA; PRIORITY JOURNAL; THROMBOSIS; VENOUS THROMBOEMBOLISM;

GERMANY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; THROMBOSIS;

EID: 60549091937     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1145252     Document Type: Editorial

References (19)

1. Schiff D. Eulogy. Eberhard Mammen, M.D. 1930-2008. Semin Thromb Hemost 2008;34:305
2. Favaloro EJ. Editorial. Semin Thromb Hemost 2008;34:307
3. Schiff D, Burgess T. Editorial. Semin Thromb Hemost 2004;30:601
4. Favaloro EJ, on behalf of the regional editors. Editorial. Semin Thromb Hemost 2008;34:693-696
5. Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008;34:7-25
6. Mammen EF, Prasad AS. [Familial dysfibrinogenemia - "Detroit fibrinogen."]. Verh Dtsch Ges Inn Med 1968;74:140-144
7. Blomback M, Blomback B, Mammen EF, Prasad AS. Fibrinogen Detroit - a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature 1968;218:134-137
8. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995;21(Suppl 2):113-121
9. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202
10. Favaloro EJ. The utility of the PFA-100 in identification of von Willebrand disease: a concise review. Semin Thromb Hemost 2006;32:537-545
11. Favaloro EJ. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100® and VWF:CB as coupled strategies. Semin Thromb Hemost 2006;6:566-576
12. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer 1993;54:793-806
13. Balk R, Emerson T, Fourrier F, et al. Therapeutic use of antithrombin concentrate in sepsis. Semin Thromb Hemost 1998;24:183-194
14. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998;24:19-25
15. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 2008;34:459-468
16. Mammen EF. Pathogenesis of venous thrombosis. Chest 1992;102(6, Suppl):640S-644S
17. Mammen E. El tratamiento de las tromboembolias. Folia Clin Int (Barc) 1962;12:146-154
18. Timmis GC, Mammen EF, Ramos RG, et al. Hemorrhage vs rethrombosis after thrombolysis for acute myocardial infarction. Arch Intern Med 1986;146:667-672
19. Mammen EF. Why low molecular weight heparin? Semin Thromb Hemost 1990;16(Suppl):1-4